The Role of CtDNA in Gastric Cancer

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 Oct 27

PMID 36291888

Authors

Justin Mencel

Susanna Slater

Elizabeth Cartwright

Naureen Starling

Affiliations

Soon will be listed here.

Abstract

Circulating tumour DNA (ctDNA) has potential applications in gastric cancer (GC) with respect to screening, the detection of minimal residual disease (MRD) following curative surgery, and in the advanced disease setting for treatment decision making and therapeutic monitoring. It can provide a less invasive and convenient method to capture the tumoural genomic landscape compared to tissue-based next-generation DNA sequencing (NGS). In addition, ctDNA can potentially overcome the challenges of tumour heterogeneity seen with tissue-based NGS. Although the evidence for ctDNA in GC is evolving, its potential utility is far reaching and may shape the management of this disease in the future. This article will review the current and future applications of ctDNA in GC.

Citing Articles

Nanomaterials in gastric cancer: pioneering precision medicine for diagnosis, therapy, and prevention.

Liu T, Gu Y, Zhao Y, Li Y Med Oncol. 2025; 42(4):93.

PMID: 40050498 DOI: 10.1007/s12032-025-02650-3.

The chemotactic response of Caenorhabditis elegans represents a promising tool for the early detection of cancer.

Kaiglova A, Hockickova P, Bardyova Z, Rehakova R, Melnikov K, Kucharikova S Discov Oncol. 2024; 15(1):817.

PMID: 39707061 PMC: 11662101. DOI: 10.1007/s12672-024-01721-7.

Effectiveness of peritoneal lavage fluid circulating tumour cells and circulating tumour DNA in the prediction of metachronous peritoneal metastasis of gastric cancer (pT4NxM0/pT1-3N+M0) after radical resection: protocol of a prospective....

Bai L, Guan Y, Zhang Y, Gu J, Ni B, Zhang H BMJ Open. 2024; 14(10):e083659.

PMID: 39353699 PMC: 11448147. DOI: 10.1136/bmjopen-2023-083659.

Emerging Therapeutic Targets and Future Directions in Advanced Gastric Cancer: A Comprehensive Review.

Ratti M, Orlandi E, Toscani I, Vecchia S, Anselmi E, Hahne J Cancers (Basel). 2024; 16(15).

PMID: 39123420 PMC: 11311890. DOI: 10.3390/cancers16152692.

Liquid biopsy for gastric cancer: Techniques, applications, and future directions.

Diaz Del Arco C, Fernandez Acenero M, Ortega Medina L World J Gastroenterol. 2024; 30(12):1680-1705.

PMID: 38617733 PMC: 11008373. DOI: 10.3748/wjg.v30.i12.1680.

References

Leal A, van Grieken N, Palsgrove D, Phallen J, Medina J, Hruban C . White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer. Nat Commun. 2020; 11(1):525. PMC: 6985115. DOI: 10.1038/s41467-020-14310-3. View

Paterlini-Brechot P, Benali N . Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Lett. 2007; 253(2):180-204. DOI: 10.1016/j.canlet.2006.12.014. View

Wajed S, Laird P, DeMeester T . DNA methylation: an alternative pathway to cancer. Ann Surg. 2001; 234(1):10-20. PMC: 1421942. DOI: 10.1097/00000658-200107000-00003. View

Mondelo-Macia P, Castro-Santos P, Castillo-Garcia A, Muinelo-Romay L, Diaz-Pena R . Circulating Free DNA and Its Emerging Role in Autoimmune Diseases. J Pers Med. 2021; 11(2). PMC: 7924199. DOI: 10.3390/jpm11020151. View

Rawla P, Barsouk A . Epidemiology of gastric cancer: global trends, risk factors and prevention. Prz Gastroenterol. 2019; 14(1):26-38. PMC: 6444111. DOI: 10.5114/pg.2018.80001. View

Zhang Q, Shan F, Li Z, Gao J, Li Y, Shen L . A prospective study on the changes and clinical significance of pre-operative and post-operative circulating tumor cells in resectable gastric cancer. J Transl Med. 2018; 16(1):171. PMC: 6011408. DOI: 10.1186/s12967-018-1544-1. View

Hindson B, Ness K, Masquelier D, Belgrader P, Heredia N, Makarewicz A . High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. Anal Chem. 2011; 83(22):8604-10. PMC: 3216358. DOI: 10.1021/ac202028g. View

Bang Y, Van Cutsem E, Feyereislova A, Chung H, Shen L, Sawaki A . Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376(9742):687-97. DOI: 10.1016/S0140-6736(10)61121-X. View

Tug S, Helmig S, Deichmann E, Schmeier-Jurchott A, Wagner E, Zimmermann T . Exercise-induced increases in cell free DNA in human plasma originate predominantly from cells of the haematopoietic lineage. Exerc Immunol Rev. 2015; 21:164-73. View

10.

Ococks E, Frankell A, Masque Soler N, Grehan N, Northrop A, Coles H . Longitudinal tracking of 97 esophageal adenocarcinomas using liquid biopsy sampling. Ann Oncol. 2020; 32(4):522-532. DOI: 10.1016/j.annonc.2020.12.010. View

11.

Lee J, Kim M, Seong M, Kim H, Lee Y, Kang H . Plasma vs. serum in circulating tumor DNA measurement: characterization by DNA fragment sizing and digital droplet polymerase chain reaction. Clin Chem Lab Med. 2019; 58(4):527-532. DOI: 10.1515/cclm-2019-0896. View

12.

Shapiro B, Chakrabarty M, COHN E, Leon S . Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease. Cancer. 1983; 51(11):2116-20. DOI: 10.1002/1097-0142(19830601)51:11<2116::aid-cncr2820511127>3.0.co;2-s. View

13.

Genovese G, Kahler A, Handsaker R, Lindberg J, Rose S, Bakhoum S . Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014; 371(26):2477-87. PMC: 4290021. DOI: 10.1056/NEJMoa1409405. View

14.

Lan Y, Chen M, Fang W, Hsieh C, Lin C, Jhang F . Clinical relevance of cell-free DNA in gastrointestinal tract malignancy. Oncotarget. 2016; 8(2):3009-3017. PMC: 5356859. DOI: 10.18632/oncotarget.13821. View

15.

Huang R, Xiao J, Pavlick D, Guo C, Yang L, Jin D . Circulating Cell-Free DNA Yield and Circulating-Tumor DNA Quantity from Liquid Biopsies of 12 139 Cancer Patients. Clin Chem. 2021; 67(11):1554-1566. DOI: 10.1093/clinchem/hvab176. View

16.

Qiu P, Poehlein C, Marton M, Laterza O, Levitan D . Measuring Tumor Mutational Burden (TMB) in Plasma from mCRPC Patients Using Two Commercial NGS Assays. Sci Rep. 2019; 9(1):114. PMC: 6331610. DOI: 10.1038/s41598-018-37128-y. View

17.

Klein E, Richards D, Cohn A, Tummala M, Lapham R, Cosgrove D . Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021; 32(9):1167-1177. DOI: 10.1016/j.annonc.2021.05.806. View

18.

Nadauld L, McDonnell 3rd C, Beer T, Liu M, Klein E, Hudnut A . The PATHFINDER Study: Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test into Clinical Practice. Cancers (Basel). 2021; 13(14). PMC: 8304888. DOI: 10.3390/cancers13143501. View

19.

Sargent D, Marsoni S, Monges G, Thibodeau S, Labianca R, Hamilton S . Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010; 28(20):3219-26. PMC: 2903323. DOI: 10.1200/JCO.2009.27.1825. View

20.

Asplund J, Kauppila J, Mattsson F, Lagergren J . Survival Trends in Gastric Adenocarcinoma: A Population-Based Study in Sweden. Ann Surg Oncol. 2018; 25(9):2693-2702. PMC: 6097732. DOI: 10.1245/s10434-018-6627-y. View